Congratulations to our client Orasis Pharmaceuticals, on its successful completion of $78m financing.
The financing included a $68m equity component, co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc., with participation by other new and existing investors, as well as $15m in structured capital from Catalio Capital Management.
The team representing Orasis in this transaction: Shmulik Atias, Yair Hadar and May Grinfeld from our International and Hi-Tech Department and Ariel Rosenberg and Yuval Levin from our ,Corporate, Finance and Infrastructure Department.
